Andrew H Wei

List of Publications by Year
in descending order

272	26,478	25034 57	6836 155
papers	citations	h-index	g-index

281	281	281	20962
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood, 2017, 129, 424-447.	1.4	4,375
2	Differential Targeting of Prosurvival Bcl-2 Proteins by Their BH3-Only Ligands Allows Complementary Apoptotic Function. Molecular Cell, 2005, 17, 393-403.	9.7	1,639
3	Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with aFLT3Mutation. New England Journal of Medicine, 2017, 377, 454-464.	27.0	1,628
4	Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. New England Journal of Medicine, 2017, 376, 836-847.	27.0	1,443
5	Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. New England Journal of Medicine, 2020, 383, 617-629.	27.0	1,407
6	Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood, 2019, 133, 7-17.	1.4	1,254
7	The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell, 2006, 10, 389-399.	16.8	1,149
8	Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes and Development, 2005, 19, 1294-1305.	5.9	1,071
9	The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. Nature, 2016, 538, 477-482.	27.8	830
10	International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood, 2022, 140, 1200-1228.	1.4	814
11	Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood, 2022, 140, 1345-1377.	1.4	805
12	Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncology, The, 2018, 19, 216-228.	10.7	551
13	Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study. Journal of Clinical Oncology, 2019, 37, 1277-1284.	1.6	494
14	Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood, 2020, 135, 2137-2145.	1.4	470
15	Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood, 2020, 135, 791-803.	1.4	412
16	Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia. Genes and Development, 2012, 26, 120-125.	5.9	344
17	AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies. Cancer Discovery, 2018, 8, 1582-1597.	9.4	310
18	Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission. New England Journal of Medicine, 2020, 383, 2526-2537.	27.0	265

#	Article	IF	Citations
19	BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines. Cancer Cell, 2018, 34, 879-891.	16.8	250
20	Inhibition of Endosteal Vascular Niche Remodeling Rescues Hematopoietic Stem Cell Loss in AML. Cell Stem Cell, 2018, 22, 64-77.e6.	11.1	249
21	MDM2 inhibition: an important step forward in cancer therapy. Leukemia, 2020, 34, 2858-2874.	7.2	207
22	Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 8071-8076.	7.1	195
23	How I treat acute myeloid leukemia in the era of new drugs. Blood, 2020, 135, 85-96.	1.4	172
24	The caspase-8 inhibitor emricasan combines with the SMAC mimetic birinapant to induce necroptosis and treat acute myeloid leukemia. Science Translational Medicine, 2016, 8, 339ra69.	12.4	140
25	Towards precision medicine for AML. Nature Reviews Clinical Oncology, 2021, 18, 577-590.	27.6	138
26	In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 17961-17966.	7.1	137
27	Targeting MCL-1 in hematologic malignancies: Rationale and progress. Blood Reviews, 2020, 44, 100672.	5.7	135
28	Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study. Lancet Oncology, The, 2015, 16, 1025-1036.	10.7	129
29	Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia. Blood, 2020, 135, 371-380.	1.4	127
30	Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia. Leukemia, 2019, 33, 905-917.	7.2	126
31	Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1. Leukemia, 2018, 32, 303-312.	7.2	123
32	Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): A Phase Ib Dose-Escalation Study of Venetoclax Combined With Modified Intensive Chemotherapy. Journal of Clinical Oncology, 2020, 38, 3506-3517.	1.6	112
33	Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML. Blood, 2017, 130, 2469-2474.	1.4	110
34	The Multi-Kinase Inhibitor Midostaurin (M) Prolongs Survival Compared with Placebo (P) in Combination with Daunorubicin (D)/Cytarabine (C) Induction (ind), High-Dose C Consolidation (consol), and As Maintenance (maint) Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients (pts) Age 18-60 with FLT3 Mutations (muts): An International Prospective Randomized (rand) P-Controlled Double-Blind Trial (CALGB 10603/RATIFY [Alliance]). Blood, 2015, 126, 6-6.	1.4	104
35	RUNX1-mutated families show phenotype heterogeneity and a somatic mutation profile unique to germline predisposed AML. Blood Advances, 2020, 4, 1131-1144.	5.2	102
36	Granulocyte colony-stimulating factorâ€“induced sickle cell crisis and multiorgan dysfunction in a patient with compound heterozygous sickle cell/Î²+ thalassemia. Blood, 2001, 97, 3998-3999.	1.4	101

#	Article	IF	Citations
37	Structural Basis for Apoptosis Inhibition by Epstein-Barr Virus BHRF1. PLoS Pathogens, 2010, 6, e1001236.	4.7	99
38	Genomic subtyping and therapeutic targeting of acute erythroleukemia. Nature Genetics, 2019, 51, 694-704.	21.4	97
39	New directions for emerging therapies in acute myeloid leukemia: the next chapter. Blood Cancer Journal, 2020, 10, 107.	6.2	96
40	Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term followâ€up from a phase 1b study. American Journal of Hematology, 2021, 96, 208-217.	4.1	95
41	Targeting p38 or MK2 Enhances the Anti-Leukemic Activity of Smac-Mimetics. Cancer Cell, 2016, 29, 145-158.	16.8	93
42	Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial. Lancet Oncology, The, 2021, 22, 1597-1608.	10.7	90
43	Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus lowâ€dose cytosine arabinoside in elderly patients with acute myeloid leukemia. Cancer, 2013, 119, 2611-2619.	4.1	88
44	New insights into the haemostatic function of platelets. British Journal of Haematology, 2009, 147, 415-430.	2.5	81
45	Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood Cancer Journal, 2014, 4, e170-e170.	6.2	80
46	BCL2 and MCL1 inhibitors for hematologic malignancies. Blood, 2021, 138, 1120-1136.	1.4	78
47	Chromosomal Abnormalities and Prognosis in NPM1-Mutated Acute Myeloid Leukemia: A Pooled Analysis of Individual Patient Data From Nine International Cohorts. Journal of Clinical Oncology, 2019, 37, 2632-2642.	1.6	77
48	Reducing TNF Receptor 2+ Regulatory T Cells via the Combined Action of Azacitidine and the HDAC Inhibitor, Panobinostat for Clinical Benefit in Acute Myeloid Leukemia Patients. Clinical Cancer Research, 2014, 20, 724-735.	7.0	76
49	Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias. Blood, 2021, 137, 2721-2735.	1.4	75
50	Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population. Blood, 2017, 129, 2882-2895.	1.4	74
51	The BAFF receptor TACI controls IL-10 production by regulatory B cells and CLL B cells. Leukemia, 2016, 30, 163-172.	7.2	69
52	The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission. Blood, 2019, 134, LBA-3-LBA-3.	1.4	68
53	Targeting sphingosine kinase 1 induces MCL1-dependent cell death in acute myeloid leukemia. Blood, 2017, 129, 771-782.	1.4	67
54	Phase Ib Study of the Anti-TIM-3 Antibody MBG453 in Combination with Decitabine in Patients with High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML). Blood, 2019, 134, 570-570.	1.4	64

#	Article	IF	Citations
55	Lenalidomideâ€based maintenance therapy reduces TNF receptor 2 on CD4 T cells and enhances immune effector function in acute myeloid leukemia patients. American Journal of Hematology, 2014, 89, 795-802.	4.1	63
56	Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study. Leukemia, 2021, 35, 62-74.	7.2	63
57	Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with lowâ€intensity chemotherapy in acute myeloid leukaemia. British Journal of Haematology, 2021, 192, 1026-1030.	2.5	63
58	Discovery of Potent and Selective Benzothiazole Hydrazone Inhibitors of Bcl-X_L. Journal of Medicinal Chemistry, 2013, 56, 5514-5540.	6.4	60
59	Interconversion between Tumorigenic and Differentiated States in Acute Myeloid Leukemia. Cell Stem Cell, 2019, 25, 258-272.e9.	11.1	60
60	Omalizumab is effective in treating systemic mastocytosis in a nonatopic patient. Allergy: European Journal of Allergy and Clinical Immunology, 2010, 65, 926-927.	5.7	56
61	Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts. Lancet Haematology,the, 2020, 7, e601-e612.	4.6	56
62	Preliminary Results from a Phase 1 First-in-Human Study of AMG 673, a Novel Half-Life Extended (HLE) Anti-CD33/CD3 BiTEÂ® (Bispecific T-Cell Engager) in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML). Blood, 2019, 134, 833-833.	1.4	55
63	Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS): Updated Results from a Phase 1b Study. Blood, 2020, 136, 1-2.	1.4	54
64	Targeting acute myeloid leukemia by dual inhibition of PI3K signaling and Cdk9-mediated Mcl-1 transcription. Blood, 2013, 122, 738-748.	1.4	53
65	MIRROS: a randomized, placebo-controlled, Phase III trial of cytarabine Â± idasanutlin in relapsed or refractory acute myeloid leukemia. Future Oncology, 2020, 16, 807-815.	2.4	53
66	Efficacy of an Fc-modified anti-CD123 antibody (CSL362) combined with chemotherapy in xenograft models of acute myelogenous leukemia in immunodeficient mice. Haematologica, 2015, 100, 914-926.	3.5	51
67	Time to repeal and replace response criteria for acute myeloid leukemia?. Blood Reviews, 2018, 32, 416-425.	5.7	51
68	Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial. Leukemia, 2021, 35, 2539-2551.	7.2	51
69	KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study. Leukemia Research, 2016, 50, 123-131.	0.8	50
70	Inositol polyphosphate 4-phosphatase II (INPP4B) is associated with chemoresistance and poor outcome in AML. Blood, 2015, 125, 2815-2824.	1.4	47
71	Use of antibacterial prophylaxis for patients with neutropenia. Internal Medicine Journal, 2011, 41, 102-109.	0.8	45
72	Cytokine-driven loss of plasmacytoid dendritic cell function in chronic lymphocytic leukemia. Leukemia, 2014, 28, 2005-2015.	7.2	43

#	Article	IF	Citations
73	A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Treatment-NaÃ¯ve Patients with Higher-Risk Myelodysplastic Syndrome. Blood, 2019, 134, 568-568.	1.4	43
74	Impact of F LT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-NaÃ¯ve Acute Myeloid Leukemia. Clinical Cancer Research, 2022, 28, 2744-2752.	7.0	43
75	Mitochondrial inhibitors circumvent adaptive resistance to venetoclax and cytarabine combination therapy in acute myeloid leukemia. Nature Cancer, 2021, 2, 1204-1223.	13.2	42
76	Phase 1/2 Study of Venetoclax with Low-Dose Cytarabine in Treatment-Naive, Elderly Patients with Acute Myeloid Leukemia Unfit for Intensive Chemotherapy: 1-Year Outcomes. Blood, 2017, 130, 890-890.	1.4	41
77	Blinatumomab versus chemotherapy in first salvage or in later salvage for B-cell precursor acute lymphoblastic leukemia. Leukemia and Lymphoma, 2019, 60, 2214-2222.	1.3	40
78	Safety, Efficacy, and Patient-Reported Outcomes of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome: A Phase 1b Study. Blood, 2020, 136, 55-57.	1.4	40
79	Safety and Efficacy of Venetoclax Plus Low-Dose Cytarabine in Treatment-Naive Patients Aged â‰¥65 Years with Acute Myeloid Leukemia. Blood, 2016, 128, 102-102.	1.4	40
80	New drugs creating new challenges in acute myeloid leukemia. Genes Chromosomes and Cancer, 2019, 58, 903-914.	2.8	39
81	Bone marrow immunohistology of plasma cell neoplasms. Journal of Clinical Pathology, 2003, 56, 406-411.	2.0	38
82	Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease status. Blood, 2022, 139, 2145-2155.	1.4	38
83	Enasidenib Plus Azacitidine Significantly Improves Complete Remission and Overall Response Compared with Azacitidine Alone in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) with Isocitrate Dehydrogenase 2 (IDH2) Mutations: Interim Phase II Results from an Ongoing, Randomized Study. Blood, 2019, 134, 643-643.	1.4	37
84	Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia. Future Oncology, 2016, 12, 293-302.	2.4	36
85	High expression of HMGA2 independently predicts poor clinical outcomes in acute myeloid leukemia. Blood Cancer Journal, 2018, 8, 68.	6.2	36
86	Serine Biosynthesis Is a Metabolic Vulnerability in FLT3-ITDâ€“Driven Acute Myeloid Leukemia. Cancer Discovery, 2021, 11, 1582-1599.	9.4	35
87	Discovery and SAR of novel pyrazolo[1,5-a]pyrimidines as inhibitors of CDK9. Bioorganic and Medicinal Chemistry, 2015, 23, 6280-6296.	3.0	34
88	Isavuconazole as salvage therapy for mucormycosis. Medical Mycology Case Reports, 2016, 11, 36-39.	1.3	34
89	Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial. Blood Advances, 2020, 4, 4945-4954.	5.2	34
90	Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL. Blood, 2022, 139, 1198-1207.	1.4	34

#	Article	IF	Citations
91	Results of a phase 1b study of venetoclax plus decitabine or azacitidine in untreated acute myeloid leukemia patients â‰¥ 65 years ineligible for standard induction therapy.. Journal of Clinical Oncology, 2016, 34, 7009-7009.	1.6	33
92	BCL-2 family protein BOK is a positive regulator of uridine metabolism in mammals. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 15469-15474.	7.1	31
93	Use of risk stratification to guide ambulatory management of neutropenic fever. Internal Medicine Journal, 2011, 41, 82-89.	0.8	30
94	Venetoclax with Low-Dose Cytarabine Induces Rapid, Deep, and Durable Responses in Previously Untreated Older Adults with AML Ineligible for Intensive Chemotherapy. Blood, 2018, 132, 284-284.	1.4	30
95	Maintenance lenalidomide in combination with 5â€azacitidine as postâ€remission therapy for acute myeloid leukaemia. British Journal of Haematology, 2015, 169, 199-210.	2.5	29
96	Venetoclax in Combination with Hypomethylating Agents Induces Rapid, Deep, and Durable Responses in Patients with AML Ineligible for Intensive Therapy. Blood, 2018, 132, 285-285.	1.4	29
97	Effect of enasidenib (ENA) plus azacitidine (AZA) on complete remission and overall response versus AZA monotherapy in mutant-IDH2 (mIDH2) newly diagnosed acute myeloid leukemia (ND-AML).. Journal of Clinical Oncology, 2020, 38, 7501-7501.	1.6	29
98	Cotargeting BCL-2 and MCL-1 in high-risk B-ALL. Blood Advances, 2020, 4, 2762-2767.	5.2	28
99	Acute Myeloid Leukemia: Historical Perspective and Progress in Research and Therapy Over 5 Decades. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 580-597.	0.4	28
100	Harnessing the benefits of available targeted therapies in acute myeloid leukaemia. Lancet Haematology,the, 2021, 8, e922-e933.	4.6	27
101	Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial. Blood, 2023, 141, 156-167.	1.4	27
102	Subversion of the Bcl-2 Life/Death Switch in Cancer Development and Therapy. Cold Spring Harbor Symposia on Quantitative Biology, 2005, 70, 469-477.	1.1	26
103	Clinical impact of NPM1-mutant molecular persistence after chemotherapy for acute myeloid leukemia. Blood Advances, 2021, 5, 5107-5111.	5.2	25
104	Treatment-free remission after ceasing venetoclax-based therapy in patients with acute myeloid leukemia. Blood Advances, 2022, 6, 3879-3883.	5.2	25
105	Fli-1 Overexpression in Hematopoietic Progenitors Deregulates T Cell Development and Induces Pre-T Cell Lymphoblastic Leukaemia/Lymphoma. PLoS ONE, 2013, 8, e62346.	2.5	24
106	Improving the transition of highly complex patients into the community: impact of a pharmacist in an allogeneic stem cell transplant (SCT) outpatient clinic. Supportive Care in Cancer, 2013, 21, 3491-3495.	2.2	23
107	Olutasidenib (FT-2102), an IDH1m Inhibitor As a Single Agent or in Combination with Azacitidine, Induces Deep Clinical Responses with Mutation Clearance in Patients with Acute Myeloid Leukemia Treated in a Phase 1 Dose Escalation and Expansion Study. Blood, 2019, 134, 231-231.	1.4	23
108	GADD45A methylation predicts poor overall survival in acute myeloid leukemia and is associated with IDH1/2 and DNMT3A mutations. Leukemia, 2013, 27, 1588-1592.	7.2	22

#	Article	IF	Citations
109	Phase Ib/2 study of venetoclax with low-dose cytarabine in treatment-naive patients age â‰¥ 65 with acute myelogenous leukemia.. Journal of Clinical Oncology, 2016, 34, 7007-7007.	1.6	22
110	Effectiveness of a single fixed dose of rasburicase 3â€‰<scp>mg</scp> in the management of tumour lysis syndrome. British Journal of Clinical Pharmacology, 2013, 75, 565-568.	2.4	20
111	Biomarkers associated with blinatumomab outcomes in acute lymphoblastic leukemia. Leukemia, 2021, 35, 2220-2231.	7.2	20
112	The mTOR inhibitor everolimus in combination with azacitidine in patients with relapsed/refractory acute myeloid leukemia: a phase Ib/II study. Oncotarget, 2017, 8, 52269-52280.	1.8	20
113	Protein Kinase Activity of Phosphoinositide 3-Kinase Regulates Cytokine-Dependent Cell Survival. PLoS Biology, 2013, 11, e1001515.	5.6	19
114	Development of fatal bortezomib induced acute lung injury despite concurrent therapy with high-dose dexamethasone. Leukemia and Lymphoma, 2007, 48, 212-213.	1.3	18
115	Methylation of <scp>KLF</scp>5 contributes to reduced expression in acute myeloid leukaemia and is associated with poor overall survival. British Journal of Haematology, 2013, 161, 884-888.	2.5	18
116	Pharmacologic Reduction of Mitochondrial Iron Triggers a Noncanonical BAX/BAK-Dependent Cell Death. Cancer Discovery, 2022, 12, 774-791.	9.4	18
117	Protocol of a multi-centre randomised controlled trial of a web-based information intervention with nurse-delivered telephone support for haematological cancer patients and their support persons. BMC Cancer, 2015, 15, 295.	2.6	17
118	6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy. Blood Cancer Journal, 2021, 11, 163.	6.2	17
119	FT-2102, an IDH1m Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Ayndrome (MDS): Results from a Phase 1 Study. Blood, 2018, 132, 1452-1452.	1.4	16
120	Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax Combined with Hypomethylating Agents. Blood, 2021, 138, 224-224.	1.4	16
121	PUMA promotes apoptosis of hematopoietic progenitors driving leukemic progression in a mouse model of myelodysplasia. Cell Death and Differentiation, 2016, 23, 1049-1059.	11.2	15
122	Olutasidenib (FT-2102) Induces Rapid Remissions in Patients with IDH1-Mutant Myelodysplastic Syndrome: Results of Phase 1/2 Single Agent Treatment and Combination with Azacitidine. Blood, 2019, 134, 674-674.	1.4	15
123	Rituximab responsive immune thrombocytopenic purpura in an adult with underlying autoimmune lymphoproliferative syndrome due to a splice-site mutation (IVS7+2 T>C) affecting the Fas gene. European Journal of Haematology, 2007, 79, 363-366.	2.2	14
124	Idarubicin Dose Escalation During Consolidation Therapy for Adult Acute Myeloid Leukemia. Journal of Clinical Oncology, 2017, 35, 1678-1685.	1.6	14
125	Fludarabine, cytarabine, granulocyte-colony stimulating factor and amsacrine: an effective salvage therapy option for acute myeloid leukemia at first relapse. Leukemia and Lymphoma, 2013, 54, 336-341.	1.3	13
126	Have all-trans retinoic acid and arsenic trioxide replaced all-trans retinoic acid and anthracyclines in APL as standard of care. Best Practice and Research in Clinical Haematology, 2014, 27, 39-52.	1.7	13

#	Article	IF	Citations
127	Comparison of biosimilar filgrastim with originator filgrastim for peripheral blood stem cell mobilization and engraftment in patients with multiple myeloma undergoing autologous stem cell transplantation. Transfusion, 2015, 55, 2709-2713.	1.6	13
128	Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial. Journal of Hematology and Oncology, 2021, 14, 133.	17.0	13
129	Acquired Mutations in BAX Confer Resistance to BH3 Mimetics in Acute Myeloid Leukemia. Blood, 2020, 136, 7-8.	1.4	13
130	Venetoclax exposureâ€efficacy and exposureâ€safety relationships in patients with treatmentâ€naÃ¯ve acute myeloid leukemia who are ineligible for intensive chemotherapy. Hematological Oncology, 2022, 40, 269-279.	1.7	13
131	Epigenetic Activation of Plasmacytoid DCs Drives IFNAR-Dependent Therapeutic Differentiation of AML. Cancer Discovery, 2022, 12, 1560-1579.	9.4	13
132	Phase I trials of the lysine-specific demethylase 1 inhibitor, GSK2879552, asÂmono- and combination-therapy in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes. Leukemia and Lymphoma, 2022, 63, 463-467.	1.3	13
133	Idasanutlin Plus Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia: Results of the MIRROS Trial. Blood Advances, 2022, , .	5.2	13
134	The epigenomics revolution in myelodysplasia: a clinico-pathological perspective. Pathology, 2011, 43, 536-546.	0.6	12
135	Clinicopathological aspects of therapy-related acute myeloid leukemia and myelodysplastic syndrome. Best Practice and Research in Clinical Haematology, 2019, 32, 3-12.	1.7	12
136	<scp>COVID</scp>â€19 vaccination in haematology patients: an Australian and New Zealand consensus position statement. Internal Medicine Journal, 2021, 51, 763-768.	0.8	12
137	CC-486 Prolongs Survival for Patients with Acute Myeloid Leukemia (AML) in Remission after Intensive Chemotherapy (IC) Independent of the Presence of Measurable Residual Disease (MRD) at Study Entry: Results from the QUAZAR AML-001 Maintenance Trial. Blood, 2020, 136, 32-33.	1.4	12
138	Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia. Blood Cancer Journal, 2022, 12, 71.	6.2	12
139	A Phase 1 Study of Flotetuzumab, a CD123 x CD3 DARTÂ® Protein, Combined with MGA012, an Anti-PD-1 Antibody, in Patients with Relapsed or Refractory Acute Myeloid Leukemia. Blood, 2019, 134, 2662-2662.	1.4	11
140	Results of Venetoclax and Azacitidine Combination in Chemotherapy Ineligible Untreated Patients with Acute Myeloid Leukemia with FLT3 Mutations. Blood, 2020, 136, 8-10.	1.4	11
141	Highâ€dose cytarabine (24â€‰g/m²) in combination with idarubicin (<scp>HiDAC</scp>â€3) results in high firstâ€cycle response with limited gastrointestinal toxicity in adult acute myeloid leukaemia. Internal Medicine Journal, 2013, 43, 294-297.	0.8	10
142	Safe and effective use of outpatient non-myeloablative allogeneic stem cell transplantation for myeloma. Blood Cancer Journal, 2014, 4, e213-e213.	6.2	10
143	A phase III study of venetoclax plus low-dose cytarabine in previously untreated older patients with acute myeloid leukemia (VIALE-C): A six-month update.. Journal of Clinical Oncology, 2020, 38, 7511-7511.	1.6	10
144	Oral Azacitidine (CC-486) for the Treatment of Myeloid Malignancies. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, 236-250.	0.4	10

#	Article	IF	Citations
145	Sabatolimab (MBG453) Combination Treatment Regimens for Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS): The MDS Studies in the Stimulus Immuno-Myeloid Clinical Trial Program. Blood, 2021, 138, 4669-4669.	1.4	10
146	Contemporary Approach to Acute Myeloid Leukemia Therapy in 2022. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2022, , 568-583.	3.8	10
147	Optimal approach for high-risk acute promyelocytic leukemia. Current Opinion in Hematology, 2014, 21, 102-113.	2.5	9
148	The Patientsâ€™ Perspective: Hematological Cancer Patientsâ€™ Experiences of Adverse Events as Part of Care. Journal of Patient Safety, 2021, 17, e387-e392.	1.7	9
149	Prognostic markers in coreâ€binding factor <scp>AML</scp> and improved survival with multiple consolidation cycles of intermediateâ€dose cytarabine. European Journal of Haematology, 2018, 101, 174-184.	2.2	9
150	Outcomes for Patients with Late-Stage Mutant-IDH2 (m IDH2) Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Treated with Enasidenib Vs Other Lower-Intensity Therapies in the Randomized, Phase 3 IDHentify Trial. Blood, 2021, 138, 1243-1243.	1.4	9
151	A Phase 3, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination with Azacitidine in Previously Untreated Patients with TP53-Mutant Acute Myeloid Leukemia. Blood, 2021, 138, 3426-3426.	1.4	9
152	Utility of a clinical risk score to identify highâ€risk patients with de novo acute myeloid leukaemia in first remission after highâ€dose cytarabine (Hi<scp>DAC</scp>) based induction chemotherapy. British Journal of Haematology, 2013, 160, 861-863.	2.5	8
153	Health economic impact of highâ€dose versus standardâ€dose cytarabine induction chemotherapy for acute myeloid leukaemia. Internal Medicine Journal, 2014, 44, 757-763.	0.8	8
154	Maintenance therapy for AML: are we there yet?. Blood, 2019, 133, 1390-1392.	1.4	8
155	Androgens stimulate erythropoiesis through the DNAâ€binding activity of the androgen receptor in nonâ€hematopoietic cells. European Journal of Haematology, 2020, 105, 247-254.	2.2	8
156	When Azoles Cannot Be Used: The Clinical Effectiveness of Intermittent Liposomal Amphotericin Prophylaxis in Hematology Patients. Open Forum Infectious Diseases, 2021, 8, ofab113.	0.9	8
157	Effect of olutasidenib (FT-2102) on complete remissions in patients with relapsed/refractory (R/R) mIDH1 acute myeloid leukemia (AML): Results from a planned interim analysis of a phase 2 clinical trial.. Journal of Clinical Oncology, 2021, 39, 7006-7006.	1.6	8
158	MIRROS: An ongoing randomized phase 3 trial of idasanutlin + ARA-C in patients with relapsed or refractory acute myeloid leukemia.. Journal of Clinical Oncology, 2019, 37, TPS7063-TPS7063.	1.6	8
159	Therapyâ€related acute myeloid leukaemia and myelodysplastic syndrome in Victoria, Australia 2003â€“2014. Internal Medicine Journal, 2018, 48, 822-829.	0.8	7
160	Azacitidine in Combination with the mTOR Inhibitor Everolimus in Relapsed and Refractory AML. Blood, 2011, 118, 2599-2599.	1.4	7
161	Durable response with venetoclax in combination with decitabine or azacitadine in elderly patients with acute myeloid leukemia (AML).. Journal of Clinical Oncology, 2018, 36, 7010-7010.	1.6	7
162	Olutasidenib (FT-2102) in Combination with Azacitidine Induces Durable Complete Remissions in Patients with mIDH1 Acute Myeloid Leukemia. Blood, 2021, 138, 698-698.	1.4	7

#	Article	IF	Citations
163	Sabatolimab (MBG453) Dose Selection and Dose-Response Analysis in Myelodysplastic Syndrome (MDS)/Acute Myeloid Leukemia (AML): Population Pharmacokinetics (PK) Modeling and Evaluation of Clinical Efficacy/Safety By Dose. Blood, 2020, 136, 40-42.	1.4	7
164	Outcomes following venetoclaxâ€based treatment in therapyâ€related myeloid neoplasms. American Journal of Hematology, 2022, 97, 1013-1022.	4.1	7
165	Boosting platelet production. Nature Medicine, 2008, 14, 917-918.	30.7	6
166	Clinical MDR1 inhibitors enhance Smac-mimetic bioavailability to kill murine LSCs and improve survival in AML models. Blood Advances, 2020, 4, 5062-5077.	5.2	6
167	Outcomes and health care utilization of older patients with acute myeloid leukemia. Journal of Geriatric Oncology, 2021, 12, 243-249.	1.0	6
168	Improved survival with enasidenib versus standard of care in relapsed/refractory acute myeloid leukemia associated with IDH2 mutations using historical data and propensity score matching analysis. Cancer Medicine, 2021, 10, 6336-6343.	2.8	6
169	Oral azacitidine preserves favorable level of fatigue and health-related quality of life for patients with acute myeloid leukemia in remission: results from the phase 3, placebo-controlled QUAZAR AML-001 trial. Haematologica, 2021, 106, 3240-3244.	3.5	6
170	FLT3mutation Assay Laboratory Cross Validation: Results from the CALGB 10603/Ratify Trial in Patients with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML). Blood, 2018, 132, 2800-2800.	1.4	6
171	A Phase Ib Study Combining the mTOR Inhibitor Everolimus (RAD001) with Low-Dose Cytarabine In Untreated Elderly AML. Blood, 2010, 116, 3299-3299.	1.4	6
172	An MRD-stratified pediatric protocol is as deliverable in adolescents and young adults as in children with ALL. Blood Advances, 2021, 5, 5574-5583.	5.2	6
173	Bortezomib: Putting mantle cell lymphoma on death row. Leukemia and Lymphoma, 2008, 49, 657-658.	1.3	5
174	Phase Ib study of the mTOR inhibitor everolimus with low dose cytarabine in elderly acute myeloid leukemia. Leukemia and Lymphoma, 2018, 59, 493-496.	1.3	5
175	Cytogenetic and Molecular Drivers of Outcome with Venetoclax-Based Combination Therapies in Treatment-NaÃ¯ve Elderly Patients with Acute Myeloid Leukemia (AML). Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, S202.	0.4	5
176	Dissecting causes for improved survival among patients with acute myeloid leukemia in two different eras receiving identical regimens in sequential randomized studies. Blood Cancer Journal, 2018, 8, 84.	6.2	5
177	Polyclonal Heterogeneity: The New Norm for Secondary Clinical Resistance to Targeted Monotherapy in Relapsed Leukemia?. Cancer Discovery, 2019, 9, 998-1000.	9.4	5
178	Anti-Leukemic Activity of Single Agent Venetoclax in Newly Diagnosed Acute Myeloid Leukemia: A Sub-Set Analysis of the Caveat Study. Blood, 2019, 134, 462-462.	1.4	5
179	Management of Neutropenia during Venetoclax-Based Combination Treatment in Patients with Newly Diagnosed Acute Myeloid Leukemia. Blood, 2019, 134, 3897-3897.	1.4	5
180	New Drugs Bringing New Challenges to AML: A Brief Review. Journal of Personalized Medicine, 2021, 11, 1003.	2.5	5

#	Article	IF	Citations
181	Allogeneic Hematopoietic Cell Transplantation Outcomes of Patients with R/R AML or Higher-Risk MDS Treated with the TIM-3 Inhibitor MBG453 (Sabatolimab) and Hypomethylating Agents. Blood, 2021, 138, 3677-3677.	1.4	5
182	Timing of response with venetoclax combination treatment in patients with newly diagnosed acute myeloid leukemia. American Journal of Hematology, 2022, 97, .	4.1	5
183	Prosthetic pulmonary valve thrombosis in pregnancy successfully treated with thrombolysis. Internal Medicine Journal, 2008, 38, 142-143.	0.8	4
184	Disease status at autologous stem cell transplantation and the cell of origin phenotype are important predictors of outcome in patients with neurologic (central nervous system) relapse of diffuse large B-cell lymphoma undergoing autologous stem cell transplantation. Leukemia and Lymphoma, 2009, 50, 1964-1968.	1.3	4
185	Reduced-intensity conditioned allogeneic haematopoietic stem cell transplantation results in durable disease-free and overall survival in patients with poor prognosis myeloid and lymphoid malignancies: eighty-month follow-up. Bone Marrow Transplantation, 2010, 45, 1154-1160.	2.4	4
186	Risk factors for early death after high-dose cytosine arabinoside (HiDAC)-based chemotherapy for adult AML. Leukemia, 2012, 26, 362-365.	7.2	4
187	Improving the Transition to Palliative Care for Patients With Acute Leukemia. Cancer Nursing, 2017, 40, E17-E23.	1.5	4
188	â€˜Did He Who Made the Lamb Make Thee?â€™ New Developments in Treating the â€˜Fearful Symmetryâ€™ of Acute Myeloid Leukemia. Trends in Molecular Medicine, 2017, 23, 264-281.	6.7	4
189	Partial response after induction chemotherapy has clinical relevance in acute myeloid leukaemia. British Journal of Haematology, 2017, 177, 328-330.	2.5	4
190	BAX-Mutated Clonal Hematopoiesis in Patients on Long-Term Venetoclax for Relapsed/Refractory Chronic Lymphocytic Leukemia. Blood, 2020, 136, 9-10.	1.4	4
191	A Recombinant Antibody to EphA3 for the Treatment of Hematologic Malignancies: Research Update and Interim Phase 1 Study Results. Blood, 2011, 118, 4893-4893.	1.4	4
192	A Randomised Comparison of Clofarabine Versus Low Dose Ara-C As First Line Treatment for Older Patients with AML. Blood, 2012, 120, 889-889.	1.4	4
193	Health-related quality of life (HRQoL) in the phase III QUAZAR-AML-001 trial of CC-486 as maintenance therapy for patients with acute myeloid leukemia (AML) in first remission following induction chemotherapy (IC).. Journal of Clinical Oncology, 2020, 38, 7533-7533.	1.6	4
194	A Phase-Ib/II Clinical Evaluation of Ponatinib in Combination with Azacitidine in FLT3-ITD and CBL-Mutant Acute Myeloid Leukemia (PON-AZA study). Blood, 2021, 138, 2350-2350.	1.4	4
195	Rapid detection of FLT3 exon 20 tyrosine kinase domain mutations in patients with acute myeloid leukemia by high-resolution melting analysis. Leukemia and Lymphoma, 2012, 53, 1225-1229.	1.3	3
196	Sorafenib priming may augment salvage chemotherapy in relapsed and refractory FLT3-ITD-positive acute myeloid leukemia. Blood Cancer Journal, 2014, 4, e237-e237.	6.2	3
197	Treatment practice and outcomes in FLT3-mutant acute myeloid leukemia in the pre-midostaurin era: a real-world experience from Australian tertiary hospitals. Leukemia and Lymphoma, 2020, 61, 848-854.	1.3	3
198	Venetoclax and azacitidine combination in chemotherapy ineligible untreated patients with therapy-related myeloid neoplasms, antecedent myelodysplastic syndromes, or myelodysplastic/myeloproliferative neoplasms.. Journal of Clinical Oncology, 2021, 39, 7011-7011.	1.6	3

#	Article	IF	Citations
199	Harnessing the Therapeutic Value of Venetoclax: A Breakthrough Therapy in Acute Myeloid Leukemia. Journal of Clinical Oncology, 2021, 39, 2742-2748.	1.6	3
200	Rapid Elimination of NPM1 Mutant Measurable Residual Disease (MRD) Using Low Intensity Venetoclax-Based Combinations in Acute Myeloid Leukemia (AML). Blood, 2019, 134, 2648-2648.	1.4	3
201	The Impact of Sorafenib on Phospho-FLT3 Inhibition and FLT3-ITD MRD after Chemotherapy: Correlative Studies from the Phase 2 Randomized Study of Sorafenib Versus Placebo in Combination with Intensive Chemotherapy in Previously Untreated Patients with FLT3-ITD Acute Myeloid Leukemia (ALLG AMLM16). Blood, 2020, 136, 16-18.	1.4	3
202	A Phase I Study Of KB004, a Novel Non-Fucosylated humaneeredÂ® Antibody, Targeted Against The Receptor Tyrosine Kinase EphA3, In Advanced Hematologic Malignancies. Blood, 2013, 122, 3838-3838.	1.4	3
203	KB004, a Novel Non-Fucosylated HumaneeredÂ® Antibody, Targeting EphA3, Is Active and Well Tolerated in a Phase I/II Study of Advanced Hematologic Malignancies. Blood, 2014, 124, 3756-3756.	1.4	3
204	Phase 1b study of venetoclax in combination with azacitidine in patients with treatment-naÃ¯ve higher-risk myelodysplastic syndromes.. Journal of Clinical Oncology, 2018, 36, TPS7082-TPS7082.	1.6	3
205	Preliminary Results from a Phase Ib Study Exploring MDM2 Inhibitor Siremadlin (HDM201) in Combination with B-Cell Lymphoma-2 (BCL-2) Inhibitor Venetoclax in Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (HR-MDS). Blood, 2021, 138, 1283-1283.	1.4	3
206	Molecular Characteristics of Response to Olutasidenib (FT-2102) in Patients with Relapsed/Refractory mIDH1 Acute Myeloid Leukemia. Blood, 2021, 138, 2351-2351.	1.4	3
207	Overall survival by IDH2 mutant allele (R140 or R172) in patients with late-stage mutant-IDH2 relapsed or refractory acute myeloid leukemia treated with enasidenib or conventional care regimens in the phase 3 IDHENTIFY trial.. Journal of Clinical Oncology, 2022, 40, 7005-7005.	1.6	3
208	Clinical Significance of Transient Asymptomatic Elevations in Aminotransferase (TAEAT) in Oncology. American Journal of Clinical Oncology: Cancer Clinical Trials, 0, Publish Ahead of Print, .	1.3	3
209	Revisiting late relapses in acute myeloid leukemia. Leukemia and Lymphoma, 2010, 51, 735-736.	1.3	2
210	Salvaging AML with CLAG: Novel option, or more of the same?. Leukemia Research, 2011, 35, 297-298.	0.8	2
211	Limitations of targeted therapy with sorafenib in elderly high-risk myelodysplastic syndrome and acute myeloid leukemia. Leukemia and Lymphoma, 2013, 54, 675-676.	1.3	2
212	Immunological markers for prognostication in cytogenetically normal acute myeloid leukemia. American Journal of Hematology, 2015, 90, E219-20.	4.1	2
213	Incorporating Precision BH3 Warheads Into the Offensive Against Acute Myeloid Leukemia. Journal of Clinical Oncology, 2019, 37, 1785-1789.	1.6	2
214	AML-062: Long-Term Follow-Up of a Phase 1/2 Study of Venetoclax (VEN) Plus Low-Dose Cytarabine (LDAC) in Previously Untreated Older Adults with Acute Myeloid Leukemia (AML). Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, S178.	0.4	2
215	Estimating the Productivity Impact of Acute Myeloid Leukemia in Australia Between 2020 and 2029, Using a Novel Work Utility Measure: The Productivity-Adjusted Life Year (PALY). JCO Oncology Practice, 2021, 17, e1803-e1810.	2.9	2
216	Venetoclax plus low-dose cytarabine in Japanese patients with untreated acute myeloid leukaemia ineligible for intensive chemotherapy. Japanese Journal of Clinical Oncology, 2021, 51, 1372-1382.	1.3	2

#	Article	IF	Citations
217	The path to approval for oral hypomethylating agents in acute myeloid leukemia and myelodysplastic syndromes. Future Oncology, 2021, 17, 2563-2571.	2.4	2
218	Eradication of Acute Myeloid Leukemia Is Enhanced By Combined Bcl-2 and Mcl-1 Targeting. Blood, 2014, 124, 988-988.	1.4	2
219	Escalated dosing schedules of CC-486 for patients experiencing first acute myeloid leukemia (AML) relapse: Results from the phase III QUAZAR AML-001 maintenance trial.. Journal of Clinical Oncology, 2020, 38, 7513-7513.	1.6	2
220	Outpatient Non-Myeloablative Allogeneic Stem Cell Transplantation For Myeloma Is Feasible, Efficacious and Associated With Low Transplant-Related Morbidity and Mortality. Blood, 2013, 122, 2128-2128.	1.4	2
221	Do patients with haematological malignancies suffer financial burden? A cross-sectional study of patients seeking care through a publicly funded healthcare system. Leukemia Research, 2022, 112, 106748.	0.8	2
222	Evolution of Therapy for Older Patients With Acute Myeloid Leukemia. Cancer Journal (Sudbury, Mass) Tj ETQq0 0 0 rgBT /Overlock 10 T	2.6	2
223	Extranodal marginal zone bâ€cell lymphoma of mucosaâ€associated lymphoid tissue of the gallbladder. Surgical Practice, 2008, 12, 137-141.	0.2	1
224	Cardiac Imaging in FIP1L1-PDGFRA. Journal of the American College of Cardiology, 2013, 62, 1304.	2.8	1
225	ABT-199 partners with azacitidine to contest myeloid malignancies. Leukemia and Lymphoma, 2015, 56, 8-9.	1.3	1
226	Future Developments: Novel Agents. Hematologic Malignancies, 2021, , 293-315.	0.2	1
227	Fitness for intensive chemotherapy: a continuing conundrum. Blood, 2021, 138, 356-358.	1.4	1
228	Improved Overall Survival with Enasidenib Compared with Standard of Care Among Patients with Relapsed or Refractory Acute Myeloid Leukemia and IDH2 Mutations: A Propensity Score Matching Analysis Using Data from the AG221-C-001 Trial and Two Data Sources from France and Germany. Blood, 2019, 134, 3893-3893.	1.4	1
229	Determination of the Maximum Tolerated Dose of Panobinostat in Combination with a 5-Day Schedule of Azacitidine in High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia: Planned Interim Analysis of a Phase Ib/II Study. Blood, 2011, 118, 1529-1529.	1.4	1
230	Comparison of Cyclophosphamide/Total Body Irradiation (Cy/TBI) and Etoposide/Total Body Irradiation (Etop/TBI) Conditioned Allogeneic Stem Cell Transplant (alloHSCT) for Adult Acute Lymphoblastic Leukaemia (ALL), Data from an Australian Tertiary Care Centre. Blood, 2015, 126, 5543-5543.	1.4	1
231	Clinical Activity of Azacitidine In Combination with the Oral mTOR Inhibitor Everolimus (RAD001) In Relapsed and Refractory AML: Interim Analysis of a Phase Ib/II Study. Blood, 2010, 116, 3301-3301.	1.4	1
232	A Phase 1b Dose Escalation Safety Analysis of Lenalidomide and Azacitidine Maintenance Therapy for Poor Risk AML,. Blood, 2011, 118, 3625-3625.	1.4	1
233	Stage I findings of a two-stage phase II study to assess the efficacy, safety, and tolerability of barasertib (AZD1152) compared with low-dose cytosine arabinoside (LDAC) in elderly patients (pts) with acute myeloid leukemia (AML).. Journal of Clinical Oncology, 2012, 30, 6527-6527.	1.6	1
234	CC-486 is safe and well-tolerated as maintenance therapy in elderly patients (â‰¥75 years) with acute myeloid leukemia (AML) in first remission following induction chemotherapy: Results from the phase III QUAZAR AML-001 trial.. Journal of Clinical Oncology, 2020, 38, 7530-7530.	1.6	1

#	Article	IF	Citations
235	A Prospective Phase 2 Study of Venetoclax and Low Dose Ara-C (VALDAC) to Target Rising Molecular Measurable Residual Disease and Early Relapse in Acute Myeloid Leukemia. Blood, 2021, 138, 1261-1261.	1.4	1
236	An Australasian Leukemia Lymphoma Group (ALLG) Phase 2 Study to Investigate Novel Triplets to Extend Remission with Venetoclax in Elderly (INTERVENE) Acute Myeloid Leukemia. Blood, 2021, 138, 368-368.	1.4	1
237	A Phase 2, Open-Label, Multiarm, Multicenter Study to Evaluate Magrolimab Combined with Antileukemia Therapies for First-Line, Relapsed/Refractory, or Maintenance Treatment of Acute Myeloid Leukemia. Blood, 2021, 138, 3424-3424.	1.4	1
238	Health-Related Quality of Life (HRQoL) during Treatment with Enasidenib (ENA) Plus Azacitidine (AZA) in Patients with Newly Diagnosed Mutant IDH2 (m IDH2) Acute Myeloid Leukemia (AML) Not Eligible for Intensive Chemotherapy (IC). Blood, 2021, 138, 1244-1244.	1.4	1
239	OMNIVERSE: A Phase 1b/2 Study of Oral Azacitidine Plus Venetoclax in Patients with Relapsed/Refractory (R/R) or Newly Diagnosed (ND) Acute Myeloid Leukemia (AML). Blood, 2021, 138, 2314-2314.	1.4	1
240	Delays in Time to Deterioration of Health-Related Quality of Life Were Observed in Patients with Acute Myeloid Leukemia Receiving Venetoclax in Combination with Azacitidine or in Combination with Low-Dose Cytarabine. Blood, 2020, 136, 33-35.	1.4	1
241	Author reply. Internal Medicine Journal, 2014, 44, 825-825.	0.8	0
242	Double trouble or a silver lining? A case report of two patients with NPM1-mutated donor-derived acute myeloid leukemia (AML). Leukemia and Lymphoma, 2021, 62, 489-491.	1.3	0
243	Laboratory quality assessment of candidate gene panel testing for acute myeloid leukaemia: a joint ALLG / RCPAQAP initiative. Pathology, 2021, 53, 487-492.	0.6	0
244	Taking aim at IDH in fitter patients with AML. Blood, 2021, 137, 1706-1707.	1.4	0
245	Comparison of dose modification strategies to address expected hematologic toxicities in treatment-naÃ¯ve higher-risk (HR) MDS patients treated with venetoclax + azacitidine.. Journal of Clinical Oncology, 2021, 39, 7041-7041.	1.6	0
246	Post-transplant maintenance therapy for MDS and AML: a bridge too far or the beginning of a new era?. Leukemia and Lymphoma, 2021, 62, 3073-3077.	1.3	0
247	FLT3-ITD signals bad news for core binding factor acute myeloid leukemia unless trisomy 22 comes to the rescue. Haematologica, 2021, , .	3.5	0
248	BCL-2 Inhibition in MDS. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S104-S106.	0.4	0
249	CD 138 Immunostaining of Bone Marrow Trephine Specimens Is the Most Sensitive Method for Quantifying Marrow Involvement in Patients with Plasma Cell Dyscrasias.. Blood, 2005, 106, 5071-5071.	1.4	0
250	Initial Remission Duration Is the Most Important Predictor of Outcome Following FLAG-Amsacrine Salvage of AML in First Relapse,. Blood, 2011, 118, 3631-3631.	1.4	0
251	Methylation of a Single CpG in the GADD45A Proximal Promoter Is Associated with Poor Survival in Acute Myeloid Leukemia,. Blood, 2011, 118, 3540-3540.	1.4	0
252	Methylation of the Proximal Promoter of GADD45A Is Common in Acute Myeloid Leukemia and Is Associated with Poor Survival.. Blood, 2012, 120, 2396-2396.	1.4	0

#	Article	IF	Citations
253	A Regulatory Promoter Polymorphism and Hypermethylation of Intron 1 Are Associated with Reduced Expression of KLF5 and Inferior Survival in AML. Blood, 2012, 120, 3508-3508.	1.4	0
254	Puma Is The Critical BH3-Only Protein Mediating Apoptosis In The Nup98-HoxD13 (NHD13) Mouse Model Of Human MDS. Blood, 2013, 122, 1563-1563.	1.4	0
255	The Significance of GADD45A Promoter DNA Hypermethylation in AML: Association with IDH1/2 and TET2 Mutation. Blood, 2014, 124, 69-69.	1.4	0
256	An international phase 3 randomized, placebo-controlled study of CC-486 (oral azacitidine) maintenance therapy in patients with acute myeloid leukemia (AML) in complete remission (CR): The Quazar AML maintenance trial.. Journal of Clinical Oncology, 2015, 33, TPS7097-TPS7097.	1.6	0
257	Prognostic Markers in Core-Binding Factor Acute Myeloid Leukaemia. Blood, 2015, 126, 2599-2599.	1.4	0
258	Hypermethylation of GADD45A Defines a Methylation Profile Distinct to Mutant IDH1/2, and Correlates with More Aggressive AML. Blood, 2016, 128, 2877-2877.	1.4	0
259	Increased Idarubicin Dosage during Consolidation Therapy for Adult Acute Myeloid Leukemia Improves Leukemia-Free Survival. Blood, 2016, 128, 338-338.	1.4	0
260	Development of a Data Portal for Aggregation and Analysis of Genomics Data in Familial Platelet Disorder with Predisposition to Myeloid Malignancy - the RUNX1.DB. Blood, 2018, 132, 5241-5241.	1.4	0
261	Targeting Aurora Kinase B with AZD2811 Enhances Venetoclax Activity in TP53-Mutant AML. Blood, 2019, 134, 3930-3930.	1.4	0
262	Timing of response to venetoclax combination treatment in older patients with acute myeloid leukemia.. Journal of Clinical Oncology, 2020, 38, 7531-7531.	1.6	0
263	Outcome of Therapy-Related Myeloid Neoplasms with Venetoclax-Based Therapy. Blood, 2021, 138, 36-36.	1.4	0
264	High Sensitivity Detection of FLT3-ITD Measurable Residual Disease By Deep Sequencing Prior to Hematopoietic Cell Transplant Is Highly Prognostic for Outcome in Acute Myeloid Leukemia. Blood, 2021, 138, 2364-2364.	1.4	0
265	Outcomes of nonâ€myeloablative allogeneic stem cell transplant in older patients with acute myeloid leukaemia in first remission. Internal Medicine Journal, 2021, 51, 1954-1958.	0.8	0
266	Pharmacological Reduction of Mitochondrial Iron in AML Triggers a BAX/BAK Dependent Non-Canonical Cell Death Synergistic with Venetoclax. Blood, 2021, 138, 267-267.	1.4	0
267	Venetoclax Exposure-Efficacy and Exposure-Safety Relationships in Subjects with Treatment-NaÃ¯ve Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy. Blood, 2020, 136, 52-52.	1.4	0
268	Peripheral Blood CD34+ Donor Chimerism Is Superior to CD3+ Donor Chimerism for Predicting Relapse Following Allogeneic Stem Cell Transplantation for Myeloid Malignancies. Blood, 2020, 136, 47-48.	1.4	0
269	Enhancing our chances of picking a winner in higherâ€risk myelodysplastic syndromes. British Journal of Haematology, 2022, , .	2.5	0
270	Oral azacitidine plus venetoclax in patients with relapsed/refractory or newly diagnosed acute myeloid leukemia: The phase 1b OMNIVERSE trial.. Journal of Clinical Oncology, 2022, 40, TPS7068-TPS7068.	1.6	0

#	Article	IF	Citations
271	Hyperleukocytosis associated with delayed presentation among patients with acute leukemia during the COVID-19 pandemic. Leukemia and Lymphoma, 2022, 63, 2731-2734.	1.3	0
272	Health-related quality of life (HRQoL) with enasidenib versus conventional care regimens in older patients with late-stage mutant-IDH2 relapsed or refractory acute myeloid leukemia (R/R AML).. Journal of Clinical Oncology, 2022, 40, 7032-7032.	1.6	0